Tonight, I continued watching a session from the London Calling 2024 Clinical & Biopharma Day. The expert panel’s title was “Precision oncology: driving better outcomes for patients, health systems, and populations.” Olivier Lucas, the Director of Oncology with Oxford Nanopore Technologies (ONT), moderated the discussion. The audience asked the panelists questions about sensitivity and risk determination. William Stanford from […]